AWRK6, A Synthetic Cationic Peptide Derived from Antimicrobial Peptide Dybowskin-2CDYa, Inhibits Lipopolysaccharide-Induced Inflammatory Response

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Lipopolysaccharides (LPS) are key components of Gram-negative bacteria, triggering potent inflammatory responses.
• Current antibiotics exhibit limited anti-endotoxin activity, highlighting the need for novel therapeutic agents.
• Antimicrobial peptides show potential in neutralizing LPS effects.

Purpose of the Study:

• To investigate the anti-LPS activity of the synthetic peptide AWRK6 in vitro and in vivo.
• To evaluate AWRK6's efficacy in blocking LPS binding and mitigating endotoxemia.
• To assess the safety and underlying mechanisms of AWRK6 action.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) to assess LPS binding protein (LBP) and LPS interaction.
• Murine endotoxemia model to evaluate protection against LPS challenge.
• Real-time PCR and Western blotting to analyze TLR4 and IκB signaling pathways.
• Histopathological analysis of liver and lung tissues.

Main Results:

• AWRK6 effectively inhibited LBP-LPS binding in vitro.
• AWRK6 demonstrated significant protection against endotoxemia-induced mortality in mice.
• Serum levels of LPS, IL-1β, IL-6, and TNF-α were reduced by AWRK6 treatment.
• AWRK6 reversed LPS-induced TLR4 overexpression and modulated IκB signaling.
• Histological examination revealed improved liver and lung tissue healing.
• No significant in vitro or in vivo toxicity was observed.

Conclusions:

• AWRK6 is a potent inhibitor of LPS activity, acting by blocking LPS binding to LBP.
• AWRK6 provides effective protection against LPS challenges in vitro and in vivo.
• AWRK6 represents a promising, non-toxic therapeutic strategy for managing LPS-induced inflammatory conditions.